Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers
暂无分享,去创建一个
J. Slakter | D. Barañano | R. Sergott | Allen Wolstenholme | G. Koh | S. Duparc | John T. Thompson | Justin A. Green | E. Hardaker | K. Warren | S. Rasmussen | H. Coleman | J. Patel | Alessandro Berni | H. Gevorkyan | Siôn W. Jones | A. Hussaini | J. Tonkyn | Khadeeja Mohamed | Alex Yuan | J. Ackert | Deborah S. Kelly | S. El‐Harazi
[1] W. Monteiro,et al. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria , 2019, The New England journal of medicine.
[2] F. Nosten,et al. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria , 2019, The New England journal of medicine.
[3] M. Fukuda,et al. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure , 2018, International Ophthalmology.
[4] I. Mueller,et al. The Biology of Plasmodium vivax. , 2017, Cold Spring Harbor perspectives in medicine.
[5] S. Kochar,et al. Retinopathy of vivax malaria in adults and its relation with severity parameters , 2016, Pathogens and global health.
[6] M. Marmor,et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.
[7] S. Krudsood,et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.
[8] R. Kirubakaran,et al. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. , 2013, The Cochrane database of systematic reviews.
[9] P. Leggat,et al. Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune Subjects , 2009, Antimicrobial Agents and Chemotherapy.